Navigation Links
Cephalon Statement on Federal Trade Commission Action Regarding PROVIGIL Patent Settlements
Date:2/13/2008

FRAZER, Pa., Feb. 13 /PRNewswire-FirstCall/ -- Cephalon, Inc., (Nasdaq: CEPH) issued the following statement in response to a complaint filed today by the U.S. Federal Trade Commission (FTC) in U.S. District Court for the District of Columbia challenging the validity of certain agreements entered into by the company in late 2005 and early 2006 to settle the PROVIGIL(R) (modafinil) [C-IV] patent infringement litigation and seeking to permanently enjoin the Company from maintaining or enforcing these agreements.

Cephalon stands by the strength and validity of our PROVIGIL patents and the legal basis for these settlements. We are disappointed that the FTC has determined to challenge these agreements as we believe they fully comply with both the spirit and letter of the antitrust laws. As importantly, our settlements confer a meaningful benefit to U.S. consumers by providing for the entry of generic modafinil three years early.

Cephalon is prepared to vigorously defend itself in this matter and expects to prevail.

About Cephalon, Inc.

Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of innovative products in four core therapeutic areas: central nervous system, pain, oncology and addiction. A member of the Fortune 1000, Cephalon currently employs approximately 3,000 people in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota. The company's European headquarters are located in Maisons-Alfort, France.

The company's proprietary products in the United States include: PROVIGIL, FENTORA(R) (fentanyl buccal tablet) [C-II], TRISENOX(R) (arsenic trioxide) injection, AMRIX(R) (cyclobenzaprine hydrochloride extended-release capsules), VIVITROL(R) (naltrexone fo
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cephalons 2007 Results Exceed Full Year Sales and Earnings Guidance
2. Cephalon General Counsel John E. Osborn to Resign Position
3. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
4. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
5. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
6. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Announces Strong Third Quarter Financial Results
9. Cephalon Quarterly Conference Call Invitation
10. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
11. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... April 01, 2015 Holomic is introducing ... read both chromatographic and fluorescent rapid tests with one ... high performance, quantitative readers and is already selling its ... is a first of its kind offering for manufacturers ... , Dr. Neven Karlovac, CEO of Holomic LLC, ...
(Date:4/1/2015)... 01, 2015 National recruitment firm ... of Brad Allen as Head of Sales at Optimal ... system market. , Allen brings over 20 years ... at a number of companies including Dell Services Healthcare, ... experience were a perfect fit for accomplishing the goals ...
(Date:3/31/2015)... March 31, 2015 Eastern Kentucky ... for online bachelor’s of criminal justice degree programs ... people to inspiring ideas and high quality educational ... to the University. We are confident that students ... , This is the site’s first “Students before ...
(Date:3/31/2015)... Pa. , March 31, 2015   ... by integrating Mapi,s Medical Affairs and global Risk ... from a previously announced acquisition . ... operations are conducted by a global team that ... that have decades of experience in navigating complex ...
Breaking Biology Technology:Holomic to Introduce the First Dual, Chromatographic and Fluorescent Rapid Test Reader, the HRDR-400 2Slone Partners Fills Head of Sales at Optimal Medicine 2EKU Ranked in Top 50 Among Online Criminal Justice Degrees 2Mapi expands Pharmacovigilance and Risk Management capabilities 2Mapi expands Pharmacovigilance and Risk Management capabilities 3
... Although Madison has made a deal with Georgia-based Cellnet ... not be an overnight event. Certain areas will be initially ... Square expected to be approved by the City Council in ... of Madison has taken an active role in brokering Cellnets ...
... State of Wisconsin Investment Board , which manages the 10th ... that it has preliminary approval to put up to $50 million ... between Mason Wells Biomedical Fund II and Venture ... investments with both firms $45 split between the two in ...
... recent phase-one study at UW-Madisons Waisman Center shows a ... and other neurodegenerative disorders. Their treatment could enable brain ... the bodys movement, to recover from the damage caused ... naturally occurring protein in the brain called glial cell-derived ...
Cached Biology Technology:Madison wireless deal goes forward with Cellnet 2Stem cells produce anti-disease protein in brain experiment 2
(Date:3/12/2015)... 2015 The mascots of the Atlantic Coast ... of Wake Forest Baptist Medical Center. They stopped by ... ACC Men,s Basketball Tournament. Young patients enjoyed bonding with ... their autographs. Brenner Children,s Hospital is the ... only children,s hospital in northwest North Carolina ...
(Date:3/11/2015)... , Mar. 11, 2015 Research and Markets ... the "Access Control Market by Product, Application & ... report to their offering. , This ... to reach $10.4 billion by 2020, with an estimated ... report covers the products types such as contact cards ...
(Date:3/10/2015)... , March 10, 2015 Transforming ... "Personalized Medicine in Human Space Flight" ... Thomas J. Goodwin , Ph.D. was recently featured by ... past two years. Specifically, "Personalized Medicine in ... scientific papers published in 2013 and 2014 from Springer ...
Breaking Biology News(10 mins):Global Access Control (Cards & Readers, Biometrics, Controllers, Management Software) Market 2015-2020 - Analysis of the $10 Billion Market 2"Personalized Medicine in Human Space Flight" Listed Among Most Influential Papers of 2013 and 2014 2
... Ohio scientists hope to counter the re-emerging threat of ... a research report published in the June 2010 print issue ... ), scientists show how the protein CCL5 plays a protective ... disease in the early stages of infection. CCL5 is a ...
... California, San Diego have identified a previously unknown kinase that ... major role in the progression or metastasis of cancer cells. ... 31 online Early Edition of the Proceedings of the ... professor of pathology at the UCSD School of Medicine and ...
... There have been impressive advances in computational methods, allowing ... the atomic level. In its latest Perspectives in General ... (JGP) offers an in-depth look at several of these ... membrane proteins, with special focus on ion channels. The ...
Cached Biology News:Body's own proteins may lead the way in global fight against tuberculosis 2Newly discovered kinase regulates cytoskeleton, and perhaps holds key to how cancer cells spread 2
One-step, microplate or cuvet, colorimetric, linear detection range 0.7 mg/dL to 35 mg/dL. Procedure: 5 min....
[5,6,8,9,12,14,15(n)-3H]Prostaglandin D2, 925 kBq, 25 uCi. Methanol:water:acetonitrile (3:2:1) solution.> 3.0 TBq/mmol, > 80 Ci/mmol.3.7 MBq/ml, 100 uCi/ml. Category: Radiochemicals &Radiation Safety...
One-step, microplate or cuvet, turbidometric, linear detection range 0.096 mg/dL to 11.5 mg/dL. Procedure: 5 min....
Moue Serum 8-12 Weeks Old...
Biology Products: